Benjamin Hanfstein
Overview
Explore the profile of Benjamin Hanfstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
586
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Egeli D, Hanfstein B, Lauseker M, Pfirrmann M, Saussele S, Baerlocher G, et al.
Leuk Lymphoma
. 2021 Dec;
63(4):955-962.
PMID: 34872441
SOCS gene expression at diagnosis has been suggested as a predictor of clinical outcome in chronic myeloid leukemia (CML). In this study and expression levels were determined by real-time PCR...
2.
Fabarius A, Kalmanti L, Dietz C, Lauseker M, Rinaldetti S, Haferlach C, et al.
Ann Hematol
. 2015 Sep;
94(12):2015-24.
PMID: 26385387
Major route additional cytogenetic aberrations (ACA) at diagnosis of chronic myeloid leukaemia (CML) indicate an increased risk of progression and shorter survival. Since major route ACA are almost always unbalanced,...
3.
Hecht A, Nowak D, Nowak V, Hanfstein B, Buchner T, Spiekermann K, et al.
Leuk Res
. 2015 Sep;
PMID: 26344466
To date risk stratification in acute promyelocytic leukemia (APL) is based on highly dynamic leukocyte and platelet counts only. To identify a more robust risk stratification model, a molecular risk...
4.
Saussele S, Krauss M, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, et al.
Blood
. 2015 Apr;
126(1):42-9.
PMID: 25918346
We studied the influence of comorbidities on remission rate and overall survival (OS) in patients with chronic myeloid leukemia (CML). Participants of the CML Study IV, a randomized 5-arm trial...
5.
Hanfstein B, Muller M, Hochhaus A
Ann Hematol
. 2015 Mar;
94 Suppl 2:S227-39.
PMID: 25814089
The assessment of response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) does not only reflect tumor burden at a given time but has been shown to...
6.
Hecht A, Nolte F, Nowak D, Nowak V, Reinwald M, Hanfstein B, et al.
Leuk Lymphoma
. 2014 Nov;
56(8):2289-95.
PMID: 25426668
Wilms' tumor 1 gene (WT1) is known to be highly expressed in acute promyelocytic leukemia (APL) but information on its impact on prognosis is lacking. WT1 expression was analyzed in...
7.
Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, et al.
J Cancer Res Clin Oncol
. 2014 Jun;
140(11):1965-9.
PMID: 24952896
Purpose: Chronic myeloid leukemia (CML) patients are monitored by both cytogenetic and molecular assessments, although present guidelines appear to switch from cytogenetic to molecular criteria. Due to the increasing use...
8.
Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, et al.
Haematologica
. 2014 May;
99(9):1441-7.
PMID: 24837466
The vast majority of chronic myeloid leukemia patients express a BCR-ABL1 fusion gene mRNA encoding a 210 kDa tyrosine kinase which promotes leukemic transformation. A possible differential impact of the...
9.
Proetel U, Pletsch N, Lauseker M, Muller M, Hanfstein B, Krause S, et al.
Ann Hematol
. 2014 Mar;
93(7):1167-76.
PMID: 24658964
The impact of imatinib dose on response rates and survival in older patients with chronic myeloid leukemia in chronic phase has not been studied well. We analyzed data from the...
10.
Hehlmann R, Muller M, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, et al.
J Clin Oncol
. 2013 Dec;
32(5):415-23.
PMID: 24297946
Purpose: Deep molecular response (MR(4.5)) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after treatment discontinuation. It is unclear how many patients...